TC
CBAY

TFS Capital’s Cymabay Therapeutics CBAY Stock Holding History

TFS Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-43,365
Closed -$250K – 396
2017
Q2 		$250K Buy
43,365
+4,033
+10% +$17.2K 0.1% 387
2017
Q1 		$169K Buy
+39,332
New +$113K 0.05% 524
2015
Q4 		– Sell
-21,263
Closed -$41K – 932
2015
Q3 		$41K Buy
+21,263
New +$57.9K ﹤0.01% 855

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

TFS Capital's CBAY Position: Q3 2017 in Review

TFS Capital sold out of Cymabay Therapeutics (CBAY) in Q3 2017, closing a stake of 43,365 shares — an estimated $250K sold.

TFS Capital first reported a position in CBAY in Q3 2015 and held it in 3 quarters. The position peaked at $250K in Q2 2017. 64 funds tracked by Wall St. Rank hold CBAY as of Q3 2017.

  • TFS Capital reported no remaining Cymabay Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 43,365 Cymabay Therapeutics shares in Q3 2017, an estimated $250K.
  • TFS Capital first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 3 quarters.
  • TFS Capital's Cymabay Therapeutics position peaked at $250K in Q2 2017.
  • 64 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.